Conditions: Esophageal Neoplasms
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 9
Healthy volunteers: no

Brief summary:
This is a study of an investigational agent, pemetrexed, in combination with a standard chemotherapy drug, carboplatin, for treatment of patients with metastatic esophageal cancer.

Detailed description:

Arms:
arm 1: * Pemetrexed 500 mg/m\^2 IV over 10 minutes
* Carboplatin AUC 5 IV over 30 minutes on day 1 of each cycle
* Each cycle will last 21 days.

Interventions: intervention 1: Pemetrexed intervention 2: Carboplatin
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: